Tirzepatide, an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity, works through incretin-based glucose regulation and appetite suppression
Contraindications Noted in Published Research Because IGF-1 signaling operates through cellular proliferation pathways also implicated in oncogenic processes, the literature consistently identifies active or prior malignancy, and precancerous conditions, as contraindications for IGF-1 LR3 research use
Human data: Human exposure is limited and largely unpublished
Cauda V, Engelke H, Sauer A, Arcizet D, Bruchle C, Rdler J, Bein T
100 Units = 1 ml 1 Unit = 0.01 ml Dose Calculation Examples Using a Reconstitution Calculator While the math is simple, the risk of error is high
Downtime 25 days of redness and mild swelling typical